Clinical Trial Detail

NCT ID NCT02254239
Title Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Mayo Clinic
Indications

Hodgkin's lymphoma

Therapies

Everolimus

Age Groups: adult

No variant requirements are available.